Search results
Displaying Results 2711-2720 of 16352 for "AVCJ webinar"
Baring targets $8.5b for eighth pan-Asia fund
Baring Private Equity Asia is back in the market seeking $8.5 billion for its eighth pan-regional fund, less than 15 months after closing Fund VII at $6.5 billion.
China yogurt brand secures $122m Series B
Simple Love, also known as Jian’Ai, a Chinese yogurt brand, has raised RMB800 million ($122 million) in Series B funding from Matrix Partners China, BA Capital, CITIC Agriculture Fund, and Maison Capital. They all backed the company's RMB400 million Series A last May.
China autonomous driving start-up TuSimple files for US IPO
TuSimple, a China and US-based developer of autonomous driving technology for trucks, has filed for a US IPO. Its backers include CDH Investments, Zhiping Capital, Sina Corporation, and Hong Kong hedge fund Composite Capital.
India's Dream Sports raises $400m, hits $5b valuation
Dream Sports, operator of India’s largest fantasy sports platform, has raised $400 million in funding led by TCV, D1 Capital Partners and Falcon Edge Capital. The post-deal valuation is nearly $5 billion.
Hony launches China healthcare, consumer SPAC
Hony Capital has joined a string of Chinese private equity managers with special purpose acquisition vehicles (SPACs), targeting $300 million for healthcare and consumer deals.
JC Flowers exits Asia trading platforms business
JC Flowers has agreed to sell Hong Kong-based Chi-X Asia Pacific, which operates equity trading platforms in Australia and Japan, to US-based Cboe Global Markets.
IFC to invest $25m in Gaja's fourth India fund
The International Finance Corporation (IFC) has proposed a $25 million commitment to the fourth private equity fund from India’s Gaja Capital. The target corpus is $400 million.
Invesco leads $155m round for China's Brii Biosciences
Invesco has led a $155 million Series C round for China-focused infectious diseases drug developer Brii Biosciences.
CMB, Mirae lead Series C for China biotech player EpimAb
Shanghai-based EpimAb Biotherapeutics has raised $120 million in Series C funding led by CMB International and Korea’s Mirae Asset Financial Group.
China drug development outsourcer raises $70m
Zhenge Biotech – a Shanghai-based contract development and manufacturing organization (CDMO) for large molecule drugs – has raised $70 million in Series B funding led by Qiming Venture Partners and IDG Capital.